Peer-Reviewed Publications

    An improved GC–MS method for cigarette smoke characterization using a novel cold trap, dual column, and cryofocusing system

    Rotach, M.; Rouget, E.; Crudo, J. R.
    Published
    May 1, 2015
    Link to publication
    Topic
    Summary

    Cigarette smoke is a highly complex matrix and presents analytical difficulties for the analyst performing compound identification by gas chromatography analysis coupled with mass spectrometric detection (GC–MS). The development of a novel trapping system and a modified GC–MS layout (using dual chromatographic columns and cryogenic focusing devices) has improved the chromatographic separation of volatile and semivolatile compounds found in cigarette smoke. This improvement has led to the potential to identify compounds usually masked by the solvent peak. This approach has also reduced the amount of peak overlapping by increasing the chromatographic peak capacity with the use of two capillary columns chosen for their analytical specificity.

    Related Publications

    Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System 2.2

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

    Aerosol Chemistry

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.